Ananda Pharma Plc (AQSE:ANA) has appointed Andy Rust as a commercial adviser to support its drug development and commercialisation plans.
"We are delighted to have Andy join us as a commercial adviser,” chief executive Melissa Sturgess said in a statement.
“In our determination to bring cannabinoid drugs to market, including two forthcoming NHS sponsored phase 3 clinical trials, we are ensuring we always have our focus on the prize, which means understanding the marketing and sales ramifications of all our decisions along the way."
Rust has three decades of experience in the pharmaceutical industry, with a focus on marketing and selling licensed drugs in the US pain sector.
He has held senior positions in international pharmaceutical companies and was most recently Global Head of Respiratory at Chiesi Group.
At Chiesi, he was responsible for the strategic direction and execution of the company’s respiratory portfolio, helping drive revenues beyond €1.5 billion.